Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MRTX-1133 |
Synonyms | |
Therapy Description |
MRTX-1133 selectively inhibits KRAS G12D, which results in decreased downstream signaling and potentially leads to reduced tumor growth (PMID: 34889605). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MRTX-1133 | MRTX1133|MRTX 1133 | KRAS G12D Inhibitor 16 | MRTX-1133 selectively inhibits KRAS G12D, which results in decreased downstream signaling and potentially leads to reduced tumor growth (PMID: 34889605). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS G12D | Advanced Solid Tumor | no benefit | MRTX-1133 | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing NRAS G12D were not sensitive to treatment with MRTX1133 (PMID: 37339170). | 37339170 |
HRAS G12D | Advanced Solid Tumor | no benefit | MRTX-1133 | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing HRAS G12D were not sensitive to treatment with MRTX1133 (PMID: 37339170). | 37339170 |
NRAS G12D | multiple myeloma | no benefit | MRTX-1133 | Preclinical - Cell culture | Actionable | In a preclinical study, a multiple myeloma cell line harboring NRAS G12D was not sensitive to treatment with MRTX1133 in culture (PMID: 37339170). | 37339170 |
NRAS G12D NRAS L95H | Advanced Solid Tumor | sensitive | MRTX-1133 | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing NRAS G12D and NRAS L95H were sensitive to treatment with MRTX1133, demonstrating decreased cell viability (PMID: 37339170). | 37339170 |
HRAS G12D HRAS Q95H | Advanced Solid Tumor | sensitive | MRTX-1133 | Preclinical - Cell culture | Actionable | In a preclinical study, cultured cells expressing HRAS G12D and HRAS Q95H were sensitive to treatment with MRTX1133, demonstrating decreased cell viability (PMID: 37339170). | 37339170 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05737706 | Phase Ib/II | MRTX-1133 | Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | Recruiting | USA | 0 |